Jun 2026 (Q2 FY26) — Aug 6, 2026
Intellia Therapeutics Q2 FY26 — Positive Lonvo-z Phase III Results and Nex-z Clinical Progress
Read the full callIntellia Therapeutics (NTLA) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
Intellia Therapeutics earnings: last reported Thu, 6 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 7.7 | −46.2% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | -1472.3 | −700.1 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | -107 | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown. |
Price
$11.58 +1.40% · +$0.16
Performance −53.2% 1Y
1Y: $24.75 on 17 Oct 2025 → $11.58. High $27.98 (20 Oct 2025), low $8.04 (20 Nov 2025).
- Previous close
- $11.42
- 52-week range
- $8.04 – $27.98
- One year
- −58.61%
Overview
- Symbol
- NTLA
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
Intellia Therapeutics earnings calls (NTLA)
Financials
What the filings say
Net profit, year on year: −5% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 9 | 13 | 17 | 14 | 14 | 23 | 15 | 8 |
| Expenses | 154 | 149 | 137 | 124 | 125 | 122 | 116 | 120 |
| Operating profit | -145 | -136 | -121 | -110 | -111 | -99 | -101 | -113 |
| Operating margin | −1589.0% | −1059.9% | −726.6% | −772.2% | −808.9% | −428.9% | −668.1% | −1472.3% |
| Net profit | -136 | -129 | -114 | -101 | -101 | -96 | -96 | -107 |
| EPS ($ per share) | -1.34 | — | -1.10 | -0.98 | -0.92 | — | -0.81 | -0.80 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reserves | -201 | -301 | -435 | -703 | -1,177 | -1,658 | -2,177 | -2,590 |
| Total liabilities | 69 | 64 | 149 | 254 | 285 | 251 | 319 | 171 |
| Fixed assets | 17 | 18 | 16 | 21 | 28 | 33 | 27 | 18 |
| Investments | 255 | 223 | 437 | 625 | 669 | 685 | 412 | 294 |
| Total assets | 347 | 334 | 676 | 1,294 | 1,520 | 1,301 | 1,191 | 842 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | -61 | -103 | -50 | -225 | -333 | -394 | -349 | -395 |
| Cash from investing | -261 | 25 | -214 | -551 | 160 | -31 | 126 | 228 |
| Cash from financing | 40 | 76 | 372 | 737 | 583 | 130 | 186 | 131 |
| Net cash flow | -282 | -2 | 107 | -39 | 410 | -295 | -38 | -35 |
| Capital expenditure | -6 | -7 | -4 | -13 | -14 | -14 | -6 | -1 |
| Free cash flow | -68 | -110 | -53 | -238 | -347 | -408 | -355 | -396 |
Insider filings
35 filings between Dec 11, 2025 and Oct 2, 2026.
Open market
decisions to buy or sellPurchases
$1.40M
1 purchase by 1 insider
Sales
$2.16M
18 sales by 7 insiders
33% filed under a 10b5-1 plan — scheduled in advance, not decided on the day
Compensation
not trading decisions- 14
- Award — granted as compensation
- 2
- Option exercise — converted options into shares
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| LEONARD JOHN M | — | $1.44M | Aug 21, 2026 |
| Cohen Fred E | $1.40M | — | Jan 5, 2026 |
| Dulac Edward J III | — | $234.2K | Jul 22, 2026 |
| BASTA JAMES | — | $112.4K | Mar 2, 2026 |
| Lebwohl David | — | $109.6K | Jan 5, 2026 |
| Clark Eliana | — | $96.0K | Mar 2, 2026 |
| Dube Michael P | — | $95.0K | Oct 2, 2026 |
| Schultes Birgit C | — | $78.4K | Jan 5, 2026 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Oct 2, 2026 | Dube Michael P VP, Chief Accounting Officer | Sale | 1,864 | $23.2K |
| Aug 21, 2026 | LEONARD JOHN M President and CEO | Sale 10b5-1 plan | 2,785 | $36.2K |
| Aug 20, 2026 | LEONARD JOHN M President and CEO | Sale 10b5-1 plan | 19,890 | $250.6K |
| Jul 22, 2026 | Dulac Edward J III EVP, Chief Financial Officer | Sale | 8,111 | $91.2K |
| Jul 2, 2026 | Dulac Edward J III EVP, Chief Financial Officer | Sale 10b5-1 plan | 4,677 | $84.2K |
| Jul 1, 2026 | Dube Michael P VP, Chief Accounting Officer | Sale | 2,641 | $44.3K |
| Jun 9, 2026 | Cohen Fred E Director | Award | 9,200 | $0 |
| Jun 9, 2026 | Goff Brian Director | Award | 9,200 | $0 |
| Jun 9, 2026 | Keresty Georgia Director | Award | 9,200 | $0 |
| Jun 9, 2026 | Verwiel Frank Director | Award | 9,200 | $0 |
| Jun 9, 2026 | CHASE WILLIAM J Director | Award | 9,200 | $0 |
| Jun 9, 2026 | GOODMAN JESSE Director | Award | 9,200 | $0 |
| Jun 9, 2026 | Bhanji Muna Director | Award | 9,200 | $0 |
| Mar 2, 2026 | BASTA JAMES EVP, General Counsel | Sale | 1,211 | $16.7K |
| Mar 2, 2026 | Clark Eliana EVP, Chief Technical Officer | Sale | 607 | $8.4K |
| Mar 1, 2026 | Dulac Edward J III EVP, Chief Financial Officer | Award | 61,280 | $0 |
| Mar 1, 2026 | Lebwohl David EVP, Chief Medical Officer | Award | 9,943 | $0 |
| Mar 1, 2026 | BASTA JAMES EVP, General Counsel | Award | 46,080 | $0 |
| Mar 1, 2026 | LEONARD JOHN M President and CEO | Award | 156,400 | $0 |
| Mar 1, 2026 | Clark Eliana EVP, Chief Technical Officer | Award | 7,353 | $0 |
| Mar 1, 2026 | Schultes Birgit C EVP, Chief Scientific Officer | Award | 39,200 | $0 |
| Mar 1, 2026 | Dube Michael P VP, Chief Accounting Officer | Award | 17,250 | $0 |
| Jan 5, 2026 | Dulac Edward J III EVP, Chief Financial Officer | Sale | 6,379 | $58.8K |
| Jan 5, 2026 | Clark Eliana EVP, Chief Technical Officer | Sale | 9,515 | $87.6K |
| Jan 5, 2026 | Lebwohl David EVP, Chief Medical Officer | Sale | 11,903 | $109.6K |
| Jan 5, 2026 | Cohen Fred E Director | Purchase | 150,000 | $1.40M |
| Jan 5, 2026 | BASTA JAMES EVP, General Counsel | Sale | 10,397 | $95.8K |
| Jan 5, 2026 | Schultes Birgit C EVP, Chief Scientific Officer | Sale | 8,508 | $78.4K |
| Jan 5, 2026 | LEONARD JOHN M President and CEO | Sale | 34,146 | $314.5K |
| Jan 5, 2026 | Dube Michael P VP, Chief Accounting Officer | Sale | 2,989 | $27.5K |
| Dec 12, 2025 | LEONARD JOHN M President and CEO | Option exercise 10b5-1 plan | 8,557 | $58.4K |
| Dec 11, 2025 | LEONARD JOHN M President and CEO | Sale 10b5-1 plan | 32,832 | $310.9K |
| Dec 11, 2025 | LEONARD JOHN M President and CEO | Sale 10b5-1 plan | 5,355 | $51.4K |
| Dec 11, 2025 | LEONARD JOHN M President and CEO | Sale 10b5-1 plan | 49,959 | $474.1K |
| Dec 11, 2025 | LEONARD JOHN M President and CEO | Option exercise 10b5-1 plan | 49,959 | $341.2K |
| Oct 1, 2025 | Dube Michael P VP, Chief Accounting Officer | Sale | 1,871 | $32.5K |
| Oct 1, 2025 | Schultes Birgit C EVP, Chief Scientific Officer | Sale | 31 | $539 |
| Aug 20, 2025 | CHASE WILLIAM J Director | Purchase | 100,000 | $1.00M |
| Jul 23, 2025 | Dulac Edward J III EVP, Chief Financial Officer | Sale | 7,462 | $104.6K |
| Jul 2, 2025 | Dube Michael P VP, Chief Accounting Officer | Sale | 2,503 | $24.9K |
| Jul 1, 2025 | Clark Eliana EVP, Chief Technical Officer | Sale | 1,022 | $10.0K |
| Jul 1, 2025 | GOODMAN JESSE Director | Sale 10b5-1 plan | 1,547 | $14.3K |
| Jun 30, 2025 | GOODMAN JESSE Director | Sale 10b5-1 plan | 1,547 | $14.8K |
| Jun 11, 2025 | Keresty Georgia Director | Award | 8,000 | $0 |
| Jun 11, 2025 | Goff Brian Director | Award | 8,000 | $0 |
| Jun 11, 2025 | GOODMAN JESSE Director | Award | 8,000 | $0 |
| Jun 11, 2025 | Cohen Fred E Director | Award | 8,000 | $0 |
| Jun 11, 2025 | CHASE WILLIAM J Director | Award | 8,000 | $0 |
| Jun 11, 2025 | Verwiel Frank Director | Award | 8,000 | $0 |
| Jun 11, 2025 | Bhanji Muna Director | Award | 8,000 | $0 |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for Intellia Therapeutics, Inc.
Free account. Everything above stays public.
Write why you follow Intellia Therapeutics, Inc. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading